Lifecore Biomedical Inc (LFCR)

Currency in USD
4.72
-0.01(-0.21%)
Closed·
4.720.00(0.00%)
·

LFCR Earnings

Latest Release
Aug 10, 2026
EPS / Forecast
-- / -0.23
Revenue / Forecast
-- / 31.66M
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
06/2026-0.190/--34.17M/------Free Sign Up
05/2026--/-0.228--/31.66M----Free Sign Up
03/2026-0.430/--23.19M/------Free Sign Up
02/2026-0.430/-0.26523.19M/29.43M-62.26%-21.2%Free Sign Up
11/2025-0.160/-0.15835.15M/37.05M-1.59%-5.13%Free Sign Up
09/2025-0.290/--31.11M/------Free Sign Up
08/2025-0.290/-0.32031.11M/26.35M+9.38%+18.06%Free Sign Up
05/2025-0.060/-0.04036.44M/35.36M-50%+3.05%Free Sign Up
02/2025-0.470/-0.14335.15M/33.83M-227.98%+3.9%Free Sign Up
11/2024-0.250/-0.27032.56M/30.18M+7.41%+7.89%Free Sign Up

All numbers in USD

Lifecore Biomedical Inc Earnings Call Summary for Q2/2026

  • Q2 revenue of $34.2M beat estimates by 8% but fell 6.2% YoY; full-year guidance of $120M-$125M revenue and $20.5M-$25M adjusted EBITDA reaffirmed.
  • Net loss widened to $6.2M ($0.19/share) from $1.1M ($0.06/share) YoY; adjusted EBITDA declined 5.5% to $8.6M despite cost-cutting progress.
  • Liquidity improved to $38.8M with $17.2M cash; SG&A expenses expected to decline to ~$6M quarterly in H2 from current $8M run rate.
  • Added six new programs in Q2 with 11 development programs targeting commercialization by end-2028; Alcon demand expected to double in 2027, up 200% in 2028.
  • Management projects $7M-$10M full-year free cash flow; Q4-weighted revenue expected with stronger second-half performance driven by existing orders.
Last Updated: 05/08/2026, 13:56
Read Full Transcript

FAQ

What Is Lifecore Biomedical's Earnings Per Share (TTM)?

The Lifecore Biomedical EPS (TTM) is -0.93.

When Is The Next Lifecore Biomedical Earnings Date?

Lifecore Biomedical will release its next earnings report on Aug 17, 2026.

What Is Lifecore Biomedical’s Revenue Forecasts For Upcoming Quarters?

Lifecore Biomedical’s revenue forecast is 27.37M.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.